Open AccessRole of sLOX ‐1 in intracranial artery stenosis and in predicting long‐term prognosis of acute ischemic stroke
Author(s) -
Li XianMei,
Jin PingPing,
Xue Jie,
Chen Jie,
Chen QinFen,
Luan XiaoQian,
Zhang ZengRui,
Yu TieEr,
Cai ZhengYi,
Zhao Kai,
Shao Bei
Publication year - 2018
Publication title -
brain and behavior
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.915
H-Index - 41
ISSN - 2162-3279
DOI - 10.1002/brb3.879
Subject(s) - medicine , stenosis , confounding , stroke (engine) , cardiology , acute stroke , artery , ischemic stroke , middle cerebral artery , neurology , ischemia , mechanical engineering , tissue plasminogen activator , engineering , psychiatry
Abstract Objective The role of sLOX ‐1 in acute ischemic stroke still remains unclear. This study aims to demonstrate the value of sLOX ‐1 in evaluating degrees of intracranial artery stenosis and to predict prognosis in stroke. Methods Two hundred and seventy‐two patients were included in this study and basic data were collected within 72 hr on admission. We assessed the association between sLOX ‐1 levels and stroke conditions in one‐year duration. After adjusting for potential confounders, regression analyses were performed. Results We found that sLOX ‐1 levels were increased significantly in severe patients compared to the mild stroke group ( p = .011). After adjusting confounders, sLOX ‐1 was associated with a poor functional outcome in patients with an adjusted OR of 2. 946 (95% CI , 1.788–4.856, p < .001). There was also positive correlation between sLOX ‐1 levels and the degrees of intracranial artery stenosis in the different groups ( p = .029). Conclusions Our study demonstrated that sLOX ‐1 levels could be used to evaluate the severity of stroke and the degrees of intracranial artery stenosis. Furthermore, sLOX ‐1 could be exploited to predict the long‐term functional outcome of stroke.